Shots:
- Genentech has reported the 1yr. data from the P-III (MEERKAT & SANDCAT) trials assessing vamikibart (intravitreal; 0.25 or 1mg, Q4W) vs a sham procedure for ~16wks. in adults with UME, followed by PRN treatment through wk. 52
- At 52wks., trial showed numerically greater vision gains in both trials (1EP), with sustained improvements in BCVA & central subfield thickness. About two-thirds of eligible pts needed no retreatment after 16wks., while most others required only 1 additional injection; data were presented at AAO’26
- Also, the US FDA has accepted BLA for vamikibart to treat UME based on the P-III (MEERKAT & SANDCAT) trials (PDUFA: July 2027). Regulatory review is also ongoing in EU, China & Japan
Ref: Businesswire | Image: Genentech | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
